Clinical Trial Update: Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer [Phase 2]

View source ↗

Summary

Phase II trial (RAINSPOT) evaluating zolbetuximab combined with paclitaxel and ramucirumab in CLDN18.2-positive gastric and gastroesophageal junction adenocarci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)
• Zolbetuximab (zolbetuximab)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Gastric Cancer Adenocarcinoma Metastatic, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: RECRUITING